A Single-Cohort, Phase 2 Study of Ruxolitinib in Combination With Corticosteroids for the Treatment of Steroid-Refractory Acute Graft-Versus-Host Disease
Phase of Trial: Phase II
Latest Information Update: 13 Dec 2017
At a glance
- Drugs Methylprednisolone (Primary) ; Prednisolone (Primary) ; Ruxolitinib (Primary)
- Indications Graft-versus-host disease
- Focus Registrational; Therapeutic Use
- Acronyms REACH-1
- Sponsors Incyte Corporation
- 30 Dec 2017 According to an Incyte Corporation media release, the first patient has been treated in this trial.
- 31 Oct 2017 According to an Incyte Corporation media release, results are expected in the first half of 2018.
- 08 Dec 2016 Status changed from not yet recruiting to recruiting.